Albumin-interferon alpha2b fusion protein - Tianjin SinoBiotech
Latest Information Update: 03 Jun 2016
At a glance
- Originator Tianjin SinoBiotech
- Class Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Interferon alpha 2b stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Hepatitis C
Most Recent Events
- 01 Apr 2016 Phase-I clinical trials in Hepatitis C (In volunteers) in China (SC) (NCT02781753)